Menu
Recruiting NCT05844865

Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis

No phase Interventional Peritoneal Carcinomatosis Gastrointestinal Peritoneal Carcinomatosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples).
Who it may be relevant to
Registry conditions: Peritoneal Carcinomatosis, Gastrointestinal Peritoneal Carcinomatosis. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This is a pilot study gathering and using samples and data from patients with gastrointestinal peritoneal carcinomatosis. Participants will be asked for permission to provide blood and ascites/peritoneal wash fluid, tumor samples during their planned surgical procedure.

Interventions

  • Other Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)
    Subjects with a known diagnosis of GI primary tumor with or without PC, with a planned standard of care surgery.

Primary outcome measures

  • Establishment of angioarchitechture of peritoneal lesions through Optical Coherence Tomography Angiography (OCTA) [Time frame: Up to 4 years]
  • Development of individual patient-derived peritoneal carcinomatosis (pdPC) vascularized micro-tumor (VMT) [Time frame: Up to 4 years]
Secondary outcome measures (3)
  • Compare response of therapeutic regimens in a pdPC VMT to the observed clinical response (by RECIST criteria or diagnostic laparoscopy) [Time frame: Up to 4 years]
  • Progression-Free Survival (PFS) at 6 months [Time frame: 6 months]
  • Overall Survival (OS) [Time frame: Up to 4 years]

Eligibility criteria

Inclusion criteria

  • Patients must have a GI tumor
  • Must have planned standard of care surgical procedure
  • Age ≥ 18 years.
  • Ability to understand and the willingness to sign a written informed consent

Exclusion criteria

\- Pattens who are unable to comply with the study protocol

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Basic science

Study locations

United States · 1 center
  • Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange

Identifiers

NCT: NCT05844865 · 2214 · UCI 22-92

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗